|  |  | Primary end point (%) |  |
---|
 | Number of | Number of |  |  |  |  |
---|
Study | patients studied | patients treated | ASA ticlopidine | ASA coumadin | ASA alone | P value |
---|
ISAR [84] | 517 | 626 | 1.6 | 6.2 | - | 0.01 |
FANTASTIC [85] | 473 | 485 | 5.7 | 8.6 | - | 0.37 |
STARS [86] | 1653 | 1965 | 0.5 | 2.7 | 3.6 | 0.001 |
MATTIS [87] | 350 | 350 | 5.6 | 11.0 | - | 0.07 |
Hall et al [88] | 226 | 358 | 0.8 | - | 3.9 | 0.1 |
- In the ISAR, STARS, MATTIS and Hall et al studies, the primary end point comprised cardiac death, acute myocardial infarction or repeat target vessel revascularization at 30 days. In the FANTASTIC study, the composite of death, acute myocardial infarction or stent occlusion at 6 weeks was the secondary end point and did not include repeat target revascularization.